WM — Waste Management, Inc.

Sentiment is genuinely split. The bearish side is price action: WM was -2.53% in the week, -5.68% in the month, and -10.51% over six months ending 2026-09-13, sitting in the lower third of its $194.11-$248.13 52-week range. Soft raw waste volumes, weak recycled-commodity and RFS credit pricing, RNG pipeline tie-in delays, a modest Q2 revenue miss, and a small insider sale by the Chief Accounting Officer (~$300K in early September 2026) all weigh. The bullish side is analyst support and cash generation: consensus is a Moderate Buy (~20 Buy / 15 Hold / 0 Sell), targets of $244-$259 sit well above the price, Q2 beat on EPS, margins outlook was raised, TTM free cash flow reached $3.57B, and the dividend ($0.945/qtr, 1.72% yield) keeps a defensive bid under the stock. Net: the market is waiting for evidence that volumes and RNG connections are turning before re-rating it.

Revenue growth has decelerated sharply and that is a structural fact, not a blip. YoY revenue growth ran +7.9% (Q3'24), +13.0% (Q4'24), +16.7% (Q1'25), +19.0% (Q2'25), +14.9% (Q3'25), +7.1% (Q4'25), +3.5% (Q1'26) and +3.9% (Q2'26) - from ~19% to ~4% in four quarters as the WM Healthcare Solutions/Stericycle acquisition anniversaries lap and organic volumes soften. Margin is stable-to-slightly-better, not deteriorating: operating margin was 18.74% in Q2'26 vs 18.46% in Q2'25 and 17.87% in Q1'26 vs 17.08% in Q1'25, i.e. roughly 30-80bps of YoY expansion off a Q2'24 peak of 19.75%. Note the gross-profit step change (Q4'25 29.3% -> Q1'26 40.7%) looks like a cost-of-revenue reclassification, not a real inflection - do not read it as margin magic. EPS is compounding mid-to-high single digits on a clean basis: $1.95 in Q2'26 (+8.3% YoY), $1.79 in Q1'26 (+13.3% YoY); Q3'25 ($1.49) and Q4'24 ($1.48) were both distorted down by large below-the-line charges (net income far below operating income), which understates TTM EPS of $7.09. The best line in the whole dataset is free cash flow: TTM FCF through Q2'26 is $3.573B ($1,096M + $851M + $810M + $816M) versus $2.163B in the comparable prior-year window, helped by capex discipline ($630M in Q2'26 vs $732M a year earlier) rather than just operations. Verdict: decelerating top line, flat-to-improving margins, accelerating cash conversion.

Fair, not cheap - and neutral versus its own history. As of 2026-09-13 the stock trades at 30.1x TTM EPS of $7.09, a slight discount to its 5-year average trailing P/E of 32.25x, and 3.32x sales versus a 5-year average of 3.59x. On forward numbers it looks better: 26.3x the next-FY consensus EPS of $8.11. But the PEG ratio is 6.17, and that is the honest tell - a 30x trailing multiple is being paid for roughly 4% revenue growth and ~7-8% EPS growth. EV/EBITDA is 14.4x and price/book is 8.65x, both rich in absolute terms and both a function of a leveraged, buyback-heavy balance sheet (D/E 2.35) rather than a red flag about the business. At 26x forward with a 1.7% dividend yield, the total-return math works out to roughly 9-10% a year if the multiple holds - reasonable for a 0.43-beta essential-services franchise, but there is no margin of safety if the multiple compresses toward the low-20s.

The multiple, not the earnings, is what moves this stock from here. WM has now printed an EPS beat alongside a revenue miss two quarters running, and both Q2'26 (adj. $2.02 vs $1.99) and the trimmed FY26 revenue guide say the same thing: the beat is coming from pricing and cost control, not volume. That is lower-quality growth than it looks, because it is finite - you can only cut cost so far, and pricing power eventually meets customer resistance. If revenue growth stays pinned near 4%, a 30x trailing P/E is hard to defend and the stock de-rates toward the low-to-mid 20s on forward earnings, implying roughly $170-$200. If instead the RNG grid ties complete and Healthcare Solutions synergies reach the targeted $250M annualized run-rate by 2027, EPS can compound low-double-digits and justify a high-20s forward multiple, which is where the $244-$259 analyst targets come from. Watch the gap between EPS beats and revenue misses as the cleanest quality-of-earnings signal for this name.

Clean downtrend, not yet a washout. As of 2026-09-13, RSI(14) was 31.89 - approaching oversold but not below 30 - and price sat 3.29% below the 20-day SMA, 6.24% below the 50-day, and 5.22% below the 200-day, with all three averages overhead. Six-month return was -10.51%, one-month -5.68%, one-week -2.53%, and the price sits in the lower third of the $194.11-$248.13 52-week range. This is a falling-knife setup for anyone trying to catch the bottom: the trend has not even produced one higher low yet. The first real evidence of a turn would be a reclaim of the 20-day SMA, an RSI push back above 40-45, or a higher low above the $194-$200 zone, which is the next meaningful support. Nothing in the technical picture argues for urgency today.

• Interest rates and refinancing costs: WM carries $22.28B of long-term debt with D/E at 2.35x and a current ratio of 0.907; lower rates reduce interest expense and support the multiple, while a higher-for-longer regime squeezes both free cash flow and the valuation ceiling.
• Inflation versus pricing power: WM's ability to pass through labor and fleet-maintenance cost inflation via annual price escalators is the core of its margin story. If inflation re-accelerates faster than contracts reset, the roughly 30-80bps of YoY operating margin expansion the company is currently delivering reverses.
• Recycled commodity and RFS/RIN credit prices: the recycling and renewable natural gas lines are directly exposed to volatile commodity and clean-fuel credit markets, which the live brief cites as a current headwind capping near-term revenue acceleration.
• Industrial and commercial waste volumes as a real-economy proxy: municipal and industrial collection volumes are already soft and are cyclically exposed; a manufacturing or construction slowdown feeds straight into the volume line that is currently the biggest drag on growth.
• Regulation and permitting: landfill permitting, landfill-methane emissions rules, and Renewable Fuel Standard policy shape both the cost base and the RNG investment returns; state-level recycling mandates cut both ways.
• Defensive rotation and low beta: WM's 0.43 beta makes it a bond proxy that tends to lag in risk-on rotations and lead when growth fears or rate-cut expectations dominate.

• Q3 2026 earnings, expected late October 2026 - the key read is whether pricing and cost control keep expanding operating margin while raw waste volumes stay soft, and whether FY26 revenue guidance is trimmed again.
• RNG facility completion and grid-tie milestones - the timing of pipeline connections is the single biggest swing factor in hitting multi-year free cash flow growth targets.
• WM Healthcare Solutions synergy ramp toward the targeted $250M annualized run-rate by 2027, which the live brief frames as the margin-expansion buffer against weak underlying volumes.
• The CEO transition - John J. Morris, Jr. takes over from James C. Fish, Jr. in early 2027; any change in capital allocation, M&A appetite, or sustainability spending would be re-rated by the market.
• Rate cuts, which would lower funding costs on a $22B debt stack and typically lift low-beta defensives.
• Continued capital return: the $0.945 quarterly dividend (1.72% yield) plus buybacks, backed by $3.57B of TTM free cash flow, gives an annual dividend-increase catalyst.

• Multiple compression is the biggest risk by far: paying ~30x trailing and ~26x forward earnings for ~4% revenue growth leaves the stock exposed to a de-rating toward the low-20s forward multiple, which alone implies $170-$200 even if earnings hold.
• Volume erosion: raw waste volumes are already soft; a recession hitting commercial, industrial, and construction collection would turn a pricing-and-cost-control story into a genuine earnings decline.
• Leverage and liquidity: $22.28B of long-term debt, D/E of 2.35x, and a current ratio of 0.907 leave less room for error, amplify interest-rate exposure, and cap how aggressively the company can buy back stock or pursue M&A when rates are elevated.
• Execution and commodity risk on the sustainability portfolio: recycled commodity and RIN credit price softness plus RNG pipeline tie-in delays are already capping revenue, and a further slippage would undermine the free-cash-flow growth thesis directly.
• Structural growth deceleration: revenue growth fell from ~19% YoY in Q2'25 to ~3.9% in Q2'26 as the Stericycle/WM Healthcare acquisition laps; reported growth from here reflects low-single-digit organic, which is a much weaker base for a 30x multiple.
• Leadership transition risk from the announced CEO succession in early 2027, and small but real insider selling (the Chief Accounting Officer sold 1,365 shares for ~$300K in early September 2026).

Waste Management is a wide-moat, low-beta essential-services franchise with genuinely improving cash generation - TTM free cash flow of $3.57B is up sharply year over year on capex discipline - and a dependable, growing dividend. But the price does not offer much for that quality: as of 2026-09-13 you are paying 30.1x trailing and 26.3x forward earnings for roughly 4% revenue growth and 7-8% EPS growth, with softening volumes, delayed RNG connections, and a stock in a confirmed downtrend below all three key moving averages. It is a good business at a full price, not a good entry. A patient investor gets a better risk/reward either near the $194-$200 support zone (roughly 24x forward) or after the company shows volumes stabilizing and RNG facilities actually tying into the grid.

I applied a 28x forward P/E - a deliberate discount to WM's 5-year average trailing P/E of 32.25x (adjusting that historical trailing multiple for ~7-8% earnings growth implies roughly 29-30x forward) but a premium to the current 26.3x, reflecting the wide moat and 0.43 beta against decelerating ~4% revenue growth - to next-FY consensus EPS of $8.11, giving 28 x 8.11 = $227. I cross-checked this against a simplified FCF-based DCF ($3.573B TTM free cash flow growing ~6% for five years, 2.5% terminal, ~6.5% WACC given the low beta), which lands near $213, and against analyst targets of $244-$259, which I view as too optimistic given the revenue trajectory. $227 implies roughly 28x TTM and 6% upside, consistent with my view that WM is a fairly-valued quality name rather than a bargain or a value trap.